Skip to main content
OpenTrials

Clinical trial condition

Attention-Deficit/Hyperactivity Disorder

Explore clinical trials studying Attention-Deficit/Hyperactivity Disorder. Study availability and eligibility vary by location and protocol.

61 public trials 7 recruiting studies
Refine in advanced search Browse all conditions

Attention-Deficit/Hyperactivity Disorder trial results

Completed

A Dose-Ranging, Cross-over Study of the Safety and Efficacy of ABT-089 in Adults With Attention-Deficit/Hyperactivity Disorder (ADHD)

NCT00391729

Conditions
Attention Deficit Disorder with Hyperactivity, Attention Deficit and Disruptive Behavior Disorders, Attention-Deficit/Hyperactivity Disorder, +2 more
Locations
  • Mesa, Arizona, United States
  • Lafayette, California, United States
  • Oceanside, California, United States
  • San Diego, California, United States
View all 23 locations
View Trial Details
Completed

A Dose-Ranging Study of the Efficacy of ABT-894 in Adults With Attention-Deficit/Hyperactivity Disorder (ADHD)

NCT00429091

Conditions
ADHD, Attention Deficit Disorder with Hyperactivity, Attention Deficit and Disruptive Behavior Disorders, +3 more
Locations
  • Site Reference ID/Investigator# 5965 San Francisco, California, United States
  • Site Reference ID/Investigator# 5955 Wildomar, California, United States
  • Site Reference ID/Investigator# 5974 Orlando, Florida, United States
  • Site Reference ID/Investigator# 5956 West Palm Beach, Florida, United States
View all 22 locations
View Trial Details
Completed

Treatment With Atomoxetine Hydrochloride in Children and Adolescents With ADHD

NCT00191048

Conditions
Attention Deficit Disorder with Hyperactivity, Attention Deficit and Disruptive Behavior Disorders, Attention-Deficit/Hyperactivity Disorder, +3 more
Locations
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician Rolling Hills Estate, California, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician Maitland, Florida, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician Miami, Florida, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician Libertyville, Illinois, United States
View Trial Details
Completed

Study of Atomoxetine in Children With ADHD to Assess Symptomatic and Functional Outcomes

NCT00191633

Conditions
Attention Deficit Disorder with Hyperactivity, Attention Deficit and Disruptive Behavior Disorders, Attention-Deficit/Hyperactivity Disorder, +2 more
Locations
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Calgary, Alberta, Canada
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Edmonton, Alberta, Canada
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Abbotsford British Columbia, British Columbia, Canada
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Burnaby, British Columbia, Canada
View all 19 locations
View Trial Details
Completed

Maintenance of Benefit With Atomoxetine Hydrochloride in Adolescents With ADHD

NCT00191035

Conditions
Attention Deficit Disorder with Hyperactivity, Attention Deficit and Disruptive Behavior Disorders, Attention-Deficit/Hyperactivity Disorder, +2 more
Locations
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon-Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician Pasadena, California, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon-Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician Rolling Hills Estates, California, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon-Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician Spring Valley, California, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon-Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician Norwich, Connecticut, United States
View all 21 locations
View Trial Details

Related conditions